IM-250

Pipeline

IM-250 is a novel, orally available, selective HSV-helicase primase inhibitor. Helicase primase inhibitors block unwinding of DNA in the replication fork during DNA-replication by a potentially uncompetitive mechanism of action. IM-250 binds to the helicase primase complex of HSV-1 and -2, blocking DNA-replication and therefore, preventing replication of the virus.

Significant preclinical antiviral efficacy has been demonstrated for IM-250. A favourable pharmacokinetic and safety profile was established in animal models. Results were published in top tier peer reviewed journals. The clinical program for IM-250 has successfully been initiated.

Reprint of the Science Translational Medicine Publication

Clinical Development Program

Indications Development Status
Genital herpes (oral)
Suppressive therapy/latency
Life-long infection, recurring genital ulcers and pain
  • Discovery
  • Candidate
  • IND-enabling
  • Phase 1a
  • Phase 1b
  • Phase 2
  • Phase 3
Phase 1b
Herpes encephalitis (IV)
Rare, life threatening brain inflammation caused by HSV
Phase 1
Genital herpes (oral)
Episodic therapy
Herpes labialis
Development Status
  • Discovery
  • Candidate
  • IND-enabling
  • Phase 1a
  • Phase 1b
  • Phase 2
  • Phase 3
Indications

Genital herpes (oral)

Suppressive therapy/latency

Life-long infection, recurring genital ulcers and pain

Phase 1b
Indications

Herpes encephalitis (IV)

Rare, life threatening brain inflammation caused by HSV

Phase 1
Indications

Genital herpes (oral)

Episodic therapy

Indications

Herpes labialis

Development

Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3

Indications

Genital herpes (oral)

Suppressive therapy/latency

Life-long infection, recurring genital ulcers and pain

Status

Phase 1b

Development

Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3

Indications

Herpes encephalitis (IV)

Rare, life threatening brain inflammation caused by HSV

Status

Phase 1

Development

Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3

Indications

Genital herpes (oral)

Episodic therapy

Development

Discovery Candidate IND-enabling Phase-1a Phase-1b Phase-2 Phase-3

Indications

Herpes labialis